IDEXX Laboratories generated $4.304 billion in 2025 revenue (+10% reported and organic), with full-year EPS of $13.08 (+23% reported) and operating margin expansion of 270 basis points. CAG Diagnostics recurring revenue grew 8% organic. The 2025 launch of IDEXX Cancer Dx for canine lymphoma and meaningful adoption of IDEXX inVue Dx well ahead of internal targets opened a new earlier-disease-detection paradigm.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Strategic priorities include cancer diagnostics innovation, inVue Dx installed base expansion, cloud-native software adoption, and water testing growth. 2026 EPS guidance of $14.29-$14.80. Strengths include category leadership in companion animal diagnostics, recurring revenue model with 12% premium instrument installed base growth, and the proprietary Catalyst chemistry platform supplied by Ortho through 2044. Risks include macro veterinary visit softness, FX exposure, and capital instrument cyclicality.
Topics Covered
• Corporate Overview and History
• Strategic Directions and 2026-2030 Priorities
• Financial Performance and Segment Breakdown
• SWOT Analysis
• Business Segment Analysis
• Technology and Innovation Pipeline
• M&A, Partnerships and Licensing Activity
• Competitive Positioning Against Top 10 Peers
• Strategic Conclusions and Outlook
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Business Segment Analysis
7. Technology and Innovation
8. M&A and Partnerships
9. Competitive Positioning
10. Strategic Conclusions
11. Appendix
List of Tables
Table 1. IDEXX Laboratories — Consolidated Revenue and Operating Income 2021-2025
Table 2. IDEXX Laboratories — Revenue by Segment 2023-2025
Table 3. IDEXX Laboratories — Revenue by Geography 2023-2025
Table 4. IDEXX Laboratories — Top Products by Revenue 2025
Table 5. IDEXX Laboratories — R&D Investment and Pipeline 2023-2025
Table 6. IDEXX Laboratories — M&A and Licensing Activity 2023-2026
Table 7. IDEXX Laboratories — SWOT Analysis Summary
Table 8. IDEXX Laboratories — Competitive Positioning vs. Top 10 Peers
Table 9. IDEXX Laboratories — Capital Allocation 2023-2025
Table 10. IDEXX Laboratories — 2026 Guidance and Strategic Milestones
